Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Natalia Shevchenko and Olga Pavlova, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…
Abstract Number: 037 • 2023 Pediatric Rheumatology Symposium
Transcriptional Analysis of CD14+ Monocytes During Macrophage Activation Syndrome Highlights Role for Interferons and RNA Sensing in Monocytes
Susan Canny¹, Hannah DeBerg², Griffin Gessay², Ailing Lu³, Mary Eckert¹, Andrea La Bella⁴, Susan Shenoi⁵, Joyce Hui-Yuen⁶, Betsy Barnes⁷ and Jessica Hamerman², ¹Seattle Children's Hospital, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Northwell Health, Cohen Children's Medical Center, New Hyde Park, NY, ⁵Seattle Children's Hospital, Seattle, WA, ⁶Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁷Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (HLH), is a potentially fatal complication of rheumatic diseases. MAS is a dysfunctional hyperinflammatory…
Abstract Number: 119 • 2023 Pediatric Rheumatology Symposium
Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis
Kaleo Ede¹, Michael Shishov², Elisa Wershba², Nikita Goswami², Sabrina Gorry², Malin Jospeh², Lucia Mirea² and James O'neil², ¹Phoenix Children's Hosptial; University of Arizona College of Medicine- Phoenix, Phoenix, AZ, ²Phoenix Children's Hospital, Phoenix, AZ
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in childhood, affecting 1 to 22 per 100,000 children. JIA-associated uveitis is known…
Abstract Number: 038 • 2023 Pediatric Rheumatology Symposium
HLA-DRB1*15 Alleles in Systemic Juvenile Idiopathic Arthritis with Lung Disease and Macrophage Activation Syndrome in Italy
Claudia Bracaglia¹, Manuela Pardeo¹, Maria Troiano², Giuseppe Testa², Ivan Caiello¹, Arianna De Matteis³, Matteo Trevisan¹, Franco Locatelli⁴, Marco Andreani² and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Laboratory of Transplant Immunogenetics, Department of Haematology/Oncology, Cell and Gene, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ⁴Ospedale Pediatrico Bambino Gesù, Department of Hematology/Oncology, Cell and Gene Therapy, Roma, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is characterized by unique clinical features and it is considered as a polygenic autoinflammatory disease. Macrophage activation syndrome (MAS)…
Abstract Number: 122 • 2023 Pediatric Rheumatology Symposium
Juvenile Arthritis in Minnesota: Geospatial Variability and Environmental Exposures in Juvenile Idiopathic Arthritis
Colleen Correll¹, Austin Rau² and Jesse Berman², ¹University of Minnesota, Minneapolis, MN, ²University of Minnesota, Minneapolis
Background/Purpose: It is widely accepted that juvenile idiopathic arthritis (JIA) is caused by a combination of genetic and environmental factors, but the potential environmental triggers…
Abstract Number: 039 • 2023 Pediatric Rheumatology Symposium
Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score
Ana Isabel Rebollo-Giménez¹, Yulia Vyzhga², Luca Carlini³, Silvia Rosina⁴, Elisa Patrone¹, Maria Katsikas⁵, Claudia Magalhaes⁶, Dalia El-Ghoneimy⁷, Yasser El Miedany⁸, Raju Khubchandani⁹, Priyankar Pal¹⁰, Gabriele Simonini¹¹, Giovanni Filocamo¹², Maurizio Gattinara¹³, Fabrizio De Benedetti¹⁴, Davide Montin¹⁵, Adele Civino¹⁶, Muatasem Alsuweiti¹⁷, Valda Stanevicha¹⁸, Vyacheslav Chasnyk¹⁹, Ekaterina Alexeeva²⁰, Sulaiman M Al-Mayouf²¹, Soamarat Vilaiyuk²² and Angelo Ravelli²³, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattia Infiammatorie, Genova, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Hospital de Pediatria Juan P. Garrahan, Department of Immunology/Rheumatology, Buenos Aires, Argentina, ⁶São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil, ⁷Children's Hospital, Ain Shams University, Pediatric Allergy, Immunology and Rheumatology Unit, Cairo, Egypt, ⁸Ain Shams University, Department of Rheumatology and Rehabilitation, Cairo, Egypt, ⁹Jaslok Hospital and Research Centre, Department of Paediatrics, Mumbai, India, ¹⁰Institute of Child Health, Pediatric medicine, Kolkata, India, Kolkata, India, ¹¹IRCCS Meyer Children’s Hospital, Rheumatology Unit, Florence, Italy, ¹²Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milano, Italy, ¹³Istituto Gaetano Pini, Rheumatology Unit, Milano, Italy,, Genova, ¹⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵Regina Margherita Children Hospital, Immunology and Rheumatology Unit, Turin, Italy, ¹⁶Ospedale Vito Fazzi, Paediatric Immunology/Rheumatology Service, Lecce, Italy, ¹⁷King Hussein Medical Center, Department of Pediatrics - Pediatric Allergy, Immunology & Rheumatology Clinic, Amman, Jordan, ¹⁸University Children Hospital, Department of Pediatrics, Riga, Latvia, ¹⁹Saint-Petersburg State Pediatric Medical University, Department of Hospital Pediatrics, St. Petersburg, Russia, ²⁰Federal State Autonomous Institution “National Medical Research Center of Children's Health”, Ministry of Health of the Russian Federation, Moscow, Russia, ²¹King Faisal Specialist Hospital & Research Center, Alfaisal University, Department of Pediatric Rheumatology, Riyadh, Saudi Arabia, ²²Mahidol University Faculty of Medicine, Ramathibodi Hospital Department of Pediatrics, Bangkok, Thailand, ²³IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) accounts up to 15% of all patients with JIA and is distinctfrom the other disease categories due to the…
Abstract Number: 124 • 2023 Pediatric Rheumatology Symposium
JIA-Associated TMJ Arthritis, Idiopathic Condylar Resorption or Anterior Disc Displacement – a Care Provider Survey
Daria Sosna¹, Nancy Pan², Shelly Abramowicz³, Mara Becker⁴, Melissa Lerman⁵, Cory Resnick⁶, Tova Ronis⁷, Matthew Stoll⁸, Peter Stoustrup⁹, Marinka Twilt¹⁰, CARRA Registry Investigators¹¹ and For TMJaw¹², ¹Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York, NY, ³Emory University, Atlanta, GA, ⁴Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Harvard University, Boston, MA, ⁷Children's National Hospital, Chevy Chase, MD, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Aarhus University, Aarhus, Denmark, ¹⁰Alberta Children's Hospital, Calgary, AB, Canada, ¹¹CARRA, Washington, DC, ¹²TMJaw, Fullerton, CA
Background/Purpose: The temporomandibular joint (TMJ) can be affected in juvenile idiopathic arthritis (JIA) patients of any age or subtype. There have been reports of isolated…
Abstract Number: 048 • 2023 Pediatric Rheumatology Symposium
Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study
Orly Ohana¹, Itay Marmor², Liora Harel³, Shiri Rubin⁴, rotem tal⁵, Yoel Levinsky⁶, Orit Peled⁷ and Gil Amarilyo³, ¹Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, ²Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ³Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, ⁴Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁵Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁶Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁷Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include…
Abstract Number: 125 • 2023 Pediatric Rheumatology Symposium
Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic
Catherine Lavallee¹, Sabrina Gmuca² and Melissa Lerman², ¹Virginia Tech Carilion School of Medicine, ROANOKE, VA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Non-infectious pediatric uveitis is a vision threatening disease whose treatment involves both ophthalmologists and rheumatologists.In other diseases necessitating multidisciplinary care, coordinated care clinics have…
Abstract Number: 059 • 2023 Pediatric Rheumatology Symposium
Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Esraa Eloseily¹, Min-Lee Chang², Mary Ellen Riordan³, allan Russell⁴, Marc Natter², Yukiko Kimura⁵ and Grant Schulert¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Boston Children's Hospital, Boston, MA, ³Hackensack Meridian Health/ Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem. Despite recent advances, there remain key unanswered questions…
Abstract Number: 126 • 2023 Pediatric Rheumatology Symposium
Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture
Melanie Kohlheim¹, Eveline Wu², Laura Schanberg³, Vincent Del Gaizo¹, Catherine Lavallee⁴, Marc Natter⁵, Katie Clem⁶, Brian Shakley⁶ and Kevin Urban⁷, ¹CARRA, Washington, DC, ²UNC Chapel Hill, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Virginia Tech Carilion School of Medicine, ROANOKE, VA, ⁵Boston Children's Hospital, Boston, MA, ⁶LIFT 1428, Llc, Ooltewah, TN, ⁷Business Coaching for Creatives, New York, NY
Background/Purpose: The LIMIT-JIA trial aims to study if early abatacept treatment can prevent disease extension in children with recent-onset, uncomplicated, and oligoarticular or limited JIA.…
Abstract Number: 065 • 2023 Pediatric Rheumatology Symposium
Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA
Meghana Karumuri¹, Megan Quinlan-Waters², Alexandra Duell², Kelly Rogers², Sheila Angeles-Han³ and Patricia Vega-Fernandez², ¹Michigan State University, Novi, MI, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Uncontrolled uveitis can lead to visual complications in 50% of children with JIA associated uveitis (JIA-U). While arthritis and uveitis are not considered to…
Abstract Number: 128 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions
Paul Tsoukas¹, Hua Lu², Marla Mendes de Aquino², Michael Ombrello³, Lisa Strug² and Rae Yeung⁴, ¹The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a novel clinical entity presenting following SARS CoV2 infection. This study describes a subgroup of MIS-C patients…
Abstract Number: 075 • 2023 Pediatric Rheumatology Symposium
Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome
Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci², Simona Riccio², Francesco Quagliarella³, Ivan Caiello², Giusi Prencipe², Pietro Merli³, Franco Locatelli³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ³Ospedale Pediatrico Bambino Gesù, Department of Hematology/Oncology, Cell and Gene Therapy, Roma, Italy
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of different rheumatic diseases, particularly of systemic juvenile idiopathic arthritis (sJIA).Methods: We report the case of…
Abstract Number: 129 • 2023 Pediatric Rheumatology Symposium
Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)
Stephanie Wood¹, Justin Branch¹, Priscilla vasquez¹, Marietta De Guzman¹, Amanda Brown², A. Carmela Sagcal-Gironella³, Saimun Singla⁴, Andrea Ramirez⁵ and Tiphanie Vogel⁵, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Hackensack University Medical Center, Hackensack, NJ, ⁴Self, Houston, TX, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: A better understanding of the pathogenesis of polyJIA is necessary to guide more effective clinical care, such as the development of data-driven approaches to…

« Previous Page
1
…
8
9
10
11
12
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].